JaLCDOI 10.18926/AMO/31015
フルテキストURL fulltext.pdf
著者 Takahashi, Isao| Sekito, Noriko| Takeuchi, Makoto| Osada, Ken| Matsuzaki, Toshiro| Fukuda, Shunichi| Lai, Minyu| Uchida, Kozaburo| Kimura, Ikuro| Miyamoto, Kanji| Kitajima, Koichi| Sanada, Hiroshi|
抄録 <p>The rearrangement of breakpoint cluster region (ber) was examined in leukemic cells obtained from 3 patients initially diagnosed as having Ph+ acute leukemia, 2 with acute lymphocytic leukemia (ALL) and one with acute mixed leukemia. DNA was digested with Bgl II and BamH I. The ber rearrangement was present in the case of acute mixed leukemia (Case 1), but was absent in the 2 cases of ALL (Cases 2 and 3). These results suggest that Case 1 represented a type of blast crisis of chronic myelocytic leukemia which was unusual in the sense of the occurrence of a myeloid-lymphoid conversion and lack of an apparent chronic phase. Cases 2 and 3 appeared to be de novo Ph+ ALL.</p>
キーワード Ph-positive acute leukemia blast crisis with a silent chronic phase myeloidlymphoid conversion chronic myelocytic leukemia bcr-rearrangement
Amo Type Article
発行日 1988-04
出版物タイトル Acta Medica Okayama
42巻
2号
出版者 Okayama University Medical School
開始ページ 117
終了ページ 120
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 3164571
Web of Sience KeyUT A1988N237200008
JaLCDOI 10.18926/AMO/30705
フルテキストURL fulltext.pdf
著者 Takahashi, Isao| Hara, Masamichi| Uchida, Kozaburo| Takaoka, Kazuko| Watanabe, Seiichiro| Lai, Minyu| Hamasaki, Kazuhide| Kohi, Fumikazu| Kitajima, Koichi| Kimura, Ikuro| Adachi, Tomiro| Yorimitsu, Seiichi| Tokioka, Masaaki| Sanada, Hiroshi|
抄録 <p>Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%). The time required for achieving the complete remission varied from 20 to 55 days with a median of 39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks. Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients, although they were managed by symptomatic treatment. The results indicate the effectiveness of this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.</p>
キーワード aclarubicin cytosine arabinoside chemotherapy acute myelocytic leukemia
Amo Type Brief Note
発行日 1982-02
出版物タイトル Acta Medica Okayama
36巻
1号
出版者 Okayama University Medical School
開始ページ 77
終了ページ 80
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 6950658
Web of Sience KeyUT A1982NE20000009
JaLCDOI 10.18926/AMO/30319
フルテキストURL fulltext.pdf
著者 Takahashi, Isao| Oda, Yasuhiro| Lai, Minyu| Fukumoto, Mitsuhiro| Nishimura, Masataka| Yorimitsu, Seiichi| Kitajima, Koichi| Kimura, Ikuro|
抄録 <p>The combined effect of human lymphoblastoid interferon (HLBI) and anticancer agents on the growth of MOLT-4 was studied in vitro. The interferon showed a strikingly synergistic interaction in combination with aclarubicin, cytosine arabinoside or prednisolone. It was moderately synergistic in combination with adriamycin or 5-fluorouracil and tended to show additive effects with daunorubicin or vincristine. In vitro studies of combination chemotherapy with interferon and anticancer agents should yield valuable information as to the best combination for man.</p>
キーワード human lymphoblastoid interferon in vitro chemotherapy interaction of anticancer agents
Amo Type Article
発行日 1984-12
出版物タイトル Acta Medica Okayama
38巻
6号
出版者 Okayama University Medical School
開始ページ 501
終了ページ 504
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 6335349
Web of Sience KeyUT A1984TX98000002